Supplier of high-quality devices for incontinence and other pelvic disorders, American Medical Systems declared that the Japanese Ministry of Health, Labor and Welfare has approved the distribution of the GreenLight high performance system (HPS) laser therapy system in the Japanese market for enlarged prostate or Benign Prostatic Hyperplasia (BPH) treatment.
The GreenLight HPS Laser therapy system treats BPH with minimum side effects when compared to the Trans-Urethral Resection of the Prostate therapy, resulting in enhanced patient safety and clinical results for patients suffering from severe to mild BPH symptoms. The system is developed to treat patients undergoing anti-coagulation therapy and can also be used to treat glands of different sizes.
The GreenLight Laser system has the potential to cure large-sized glands with proficient surgical process times. MC Medical, Mitsubishi’s subsidiary and a distributor for less-invasive medical devices, is the exclusive distributor in the Japanese market for the system.
The Vice President and General Manager at American Medical Systems for Asia Pacific, Latin America and Canada, Mike Ryan commented that the company is happy to deliver the advanced technology for minimally invasive BPH treatment. Japan is a potential market for the GreenLight laser system as BPH is a common disorder in older Japanese men and BPH surgeries are increasing by 4% per year, he added.